Tehran (IP) - The results of the human trials phase of the Iranian COVID-19 vaccine will be clear in November, according to an Iranian health official.

Iran Press/Iran News: Answering the question of Iran Press on the details of the Iranian COVID-19 vaccine, Alireza Zali, the head of the National Headquarters for Managing and Fighting the coronavirus in Tehran said: "Three centers in Iran are working on vaccines. Animal trials of the Iranian vaccine have been carried out successfully, and we will probably see the results of the human testing phase in November."

However, due to the re-infection of some people, he said there are doubts regarding the effectiveness of vaccines produced in the world.

"Meanwhile, one of the top European companies in the field of vaccine production recently said that the coronavirus vaccine can provide safety for only 73 days," said Zali at a meeting in Tehran on Tuesday.

The Iranian official went on to say that 354 patients in Tehran became definitively re-infected after recovering from COVID-19 and the antibody levels of their blood being increased, and this may call into question the effectiveness of the coronavirus vaccine.

Regarding the restrictions on coronavirus in the Iranian capital, Zali said that many restrictions will stay in place until autumn, adding: "We are trying to prevent an increase in the spread of the disease by holding schools and universities electronically in the autumn."

Pointing to the favorable situation of COVID-19 management in Tehran, he said: "At the beginning of the outbreak of the disease, the rate of the observance of health protocols in the capital was 65%, but unfortunately with the end of the first wave of the disease, this number declined to 9%. But currently, the rate of observance of protocols in Tehran is 73%."

Regarding the buying of the Russian vaccine, Zali said that after the approval of international organizations such as the World Health Organization, Iran will take action to buy this vaccine.

Iran, self-sufficient in producing COVID-19 drugs, masks.

"We have no problem in producing drugs and we produce two drugs, Favipiravir and Remdesivir, and next week the mass production of these two drugs will begin and we are self-sufficient in producing masks," the head of the National Headquarters for Managing and Fighting the Coronavirus in Tehran concluded.

Read more:

Iranian Health Minister: production of COVID-19 vaccine in clinical trials

Iranian COVID-19 vaccine to undergo human trials: health min.